SEOM clinical guidelines for the treatment of pancreatic cancer

Clinical and Translational Oncology

Volumn 13, Issue 8, 2011, Pages 528-535

  Gómez Martín, Carlos ^a   Hidalgo, Manuel ^b,c   Tabernero, Josep ^d   Isla, Dolores ^e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Centro Integral Oncologico Clara Campal   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Diagnosis; Guidelines; Pancreatic cancer; Treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MORPHINE; OXALIPLATIN; PLACEBO; PLATINUM COMPLEX;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT OBSTRUCTION; BILIARY TRACT DRAINAGE; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOSE RESPONSE; DRUG EFFICACY; DUODENUM OBSTRUCTION; DYSPHAGIA; ENDOSCOPIC ECHOGRAPHY; GASTROINTESTINAL OBSTRUCTION; GASTROJEJUNOSTOMY; HEPATOJEJUNOSTOMY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LAPAROSCOPY; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS BIOPSY; PANCREAS CANCER; PANCREATICODUODENECTOMY; PANCREATICOJEJUNOSTOMY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADICAL RESECTION; RECOMMENDED DRUG DOSE; RECURRENCE RISK; STOMACH OBSTRUCTION; TUMOR BIOPSY; WHOLE BODY PET; FEMALE; MALE; MEDICAL SOCIETY; METASTASIS; METHODOLOGY; MORTALITY; ONCOLOGY; PANCREAS TUMOR; SEX DIFFERENCE;

FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SEX FACTORS; SOCIETIES, MEDICAL;

EID: 84855403689     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0693-y     Document Type: Article

References (29)

1. Royal RE, Wolff RA, Crane CH (2008) Pancreatic cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott, Williams and Wilkins, Philadelphia, p 1086-1124
2. Lopez-Abente G, Pollán M, Aragones N et al (2005) La situación del Cáncer en España. Ministero de Sanidad y Consumo, Madrid. http://cne.isciii.es
3. Sobin LH, Gospodarowicz M, Wittekind C et al (2009) TNM classification of malignant tumours, 7th edn. Wiley-Liss, New York
4. Pancreatic Adenocarcinoma. In: National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology, v.2.2010. www.nccn.org
5. -(1999) American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117:1463-1464
6. Tran KT, Smeenk HG, van Eijck CH et al (2004) Pylorus preserving pancreaticoduodenectomy versus Standard Whipple procedure. Ann Surg 240: 738-745
7. Seiler CA, Wagner M, Bachmann T et al (2005) Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection: long term results. Br J Surg 92:547-556 (Pubitemid 40685648)
8. Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210 (Pubitemid 38339364)
9. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267-277 (Pubitemid 46143304)
10. Neoptolemos JP, Buchler M, Stocken DD (2009) ESPAC-3(v2): a multicenter, international, openlabel, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5FU/FA) versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27:203
11. Regine WF, Winter KW, Abrams R et al (2006) RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 24:4007
12. Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2:3496-3502
13. Varadhachary GR, Wolff RA, Crane CH et al (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3487-3495
14. Loherer PJ, Powell ME, Cardenes HR et al (2008) A randomized phase III study of Gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 26:4506
15. Huguet F, Girard N, Seblain-El Guerche C et al (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27:2269-2277
16. Burris HA, Moore MJ, Anderson J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
17. Kindler HL, Niedzwiecki D, Hollis D et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617-3622
18. Philip PA, Benedetti J, Corless JL et al (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed Intergroup Trial S0205. J Clin Oncol 28:3605-3610
19. Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237
20. Cunningham D, Chau I, Stocken D et al (2005) Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 4:(Abstr PS 11)
21. Cunningham D, Chau I, Stocken D et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518
22. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
23. Bria E, Milella M, Gelibter A et al (2007) Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A metaanalysis of 20 phase 3 trials. Cancer 110:525-533 (Pubitemid 47106140)
24. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607-2615 (Pubitemid 47041235)
25. Heinemann V, Boeck S, Hinke A et al (2008) Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82
26. Banu E, Banu A, Fodor A et al (2007) Metaanalysis of randomised trials comparing Gemcitabine- based doublets versus Gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging 24:865-879 (Pubitemid 47553794)
27. Xie DR, Liang HL, Wang Y et al (2006) Metaanalysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 12:6973-6981 (Pubitemid 44834888)
28. Conroy T, Desseigne F, Ychou M et al (2010) Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus Gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28:15s (Abstr 4010)
29. Riess H, Pelzer U, Stieler J et al (2007) A randomised second line trial in patients with gemcitabine refractory advanced pancreatic cancer: CONKO 003. J Clin Oncol 25:201